These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

891 related articles for article (PubMed ID: 33637050)

  • 1. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
    Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
    BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
    Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
    BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
    Patel DA; Snedecor SJ; Tang WY; Sudharshan L; Lim JW; Cuffe R; Pulgar S; Gilchrist KA; Camejo RR; Stephens J; Nichols G
    PLoS One; 2014; 9(9):e105653. PubMed ID: 25188312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
    Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
    Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
    Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A;
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV.
    Ashta KK; Arora S; Khanna R; Raman N; Anilkumar A; Mohan C
    Curr HIV Res; 2024; 22(1):31-46. PubMed ID: 38284697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.
    You J; Wang H; Huang X; Qin Z; Deng Z; Luo J; Wang B; Li M
    PLoS One; 2016; 11(8):e0160087. PubMed ID: 27532886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dolutegravir in Mexico for special populations: A cost analysis perspective.
    Marco B; Cristina H; Cristhian R; Sigfrido R; Del Angel J; Reyes A; Isidoro P
    AIDS Rev; 2021 Jul; 23(3):126-132. PubMed ID: 34198310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
    Rusconi S; Adorni F; Tau P; Borghi V; Pecorari M; Maserati R; Francisci D; Monno L; Punzi G; Meraviglia P; Paolucci S; Di Biagio A; Bruzzone B; Mancon A; Micheli V; Zazzi M;
    J Clin Virol; 2018 Aug; 105():112-117. PubMed ID: 29957545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
    Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
    Taramasso L; Tatarelli P; Ricci E; Madeddu G; Menzaghi B; Squillace N; De Socio GV; Martinelli C; Gulminetti R; Maggi P; Orofino G; Vichi F; Di Biagio A; Bonfanti P;
    BMC Infect Dis; 2018 Jul; 18(1):357. PubMed ID: 30064371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.
    Nasreddine R; Florence E; Vandercam B; Moutschen M; Goffard JC; De Munter P; Delforge M; Marinus W; De Wit S;
    AIDS; 2020 Jul; 34(8):1151-1159. PubMed ID: 32287063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.
    Curtis L; Nichols G; Stainsby C; Lim J; Aylott A; Wynne B; Clark A; Bloch M; Maechler G; Martin-Carpenter L; Raffi F; Min S
    HIV Clin Trials; 2014; 15(5):199-208. PubMed ID: 25350958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
    Tremblay G; Chounta V; Piercy J; Holbrook T; Garib SA; Bukin EK; Punekar YS
    Value Health Reg Issues; 2018 Sep; 16():74-80. PubMed ID: 30296624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 resistance and virological failure to treatment with the integrase inhibitors bictegravir, cabotegravir, and dolutegravir: a systematic literature review.
    Blanco-Arévalo JL; García-Deltoro M; Torralba M; Vélez-Díaz-Pallarés M; Castro A; Rubio-Rodríguez D; Rubio-Terrés C
    AIDS Rev; 2024; 26(2):67-79. PubMed ID: 39134019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison.
    Vieira MC; Kumar RN; Jansen JP
    HIV Clin Trials; 2011; 12(4):175-89. PubMed ID: 22044854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
    Rutherford GW; Horvath H
    PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States.
    Butler K; Anderson SJ; Hayward O; Jacob I; Punekar YS; Evitt LA; Oglesby A
    J Manag Care Spec Pharm; 2021 Jul; 27(7):891-903. PubMed ID: 34185564
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 45.